Overview
Alpha-2-macroglobulin (A2M) is a protein in blood that can bind to certain enzymes involved in cartilage breakdown. A2M therapy concentrates this protein from your own blood and injects it into a joint or disc.
Research in people is at an early stage. Evidence for this therapy is limited or still evolving. It is usually not covered by insurance. It is not FDA-approved to treat any specific condition, and no outcome can be promised.
Please read: Evidence for this therapy is limited or still evolving. It is usually not covered by insurance, and it is not FDA-approved to treat any specific condition. No outcome can be promised. We will give you a written cost estimate before treatment.
How it works
Blood is drawn and processed to concentrate A2M, which is injected into the target area under imaging guidance.
Who it may be for
- Selected patients with osteoarthritis
- Patients who understand the early-stage evidence and self-pay costs
Your exam and imaging decide whether this treatment is appropriate for you.
What to expect
- Before: consultation and written cost estimate.
- During: blood draw, processing and injection.
- After: relative rest and gradual activity.
Recovery
Soreness for several days is common. Your instructions may differ.
Risks and side effects
Every procedure has risks. Your physician will review them with you, including:
- Pain or swelling
- Infection (rare)
- Lack of benefit
Insurance and cost
This treatment is usually self-pay. We will give you a written estimate before treatment. See accepted insurance.
Frequently asked questions
Is A2M well studied?
Human studies are limited. We will discuss what is and is not known.
Is it covered by insurance?
Usually not.
How is it different from PRP?
PRP concentrates platelets. A2M processing concentrates a specific protein.
This page is general patient education and does not replace advice from your own clinician. Individual results vary.